Impact of a PERsonalized CAse MAnagement Program for the Follow-up of Moderate and Severe aSTHma Patients on Exacerbations, Health Resource Use and Asthma Control: PERCASTHMA STUDY

Launched by MURCIASALUD · Nov 30, 2022

Keywords

ClinConnect Summary

The PERCASTHMA study is a clinical trial designed to see how a personalized case management follow-up program can help people with moderate to severe asthma. The goal is to understand if this program can reduce asthma flare-ups, improve how often patients need to use healthcare services, and enhance overall asthma control. Participants will be divided into two groups: one group will receive the personalized case management support, which includes regular check-ins and guidance from a case manager, while the other group will continue with standard care practices. Researchers will track both groups over a year to compare their asthma symptoms, treatment adherence, and quality of life.

To be eligible for this trial, participants must be at least 18 years old, have a confirmed diagnosis of asthma, and have been monitored in an asthma clinic for at least six months. Those who are interested will receive education on asthma management and use of inhalers. The case management group will regularly complete questionnaires about their asthma control and treatment adherence, and they'll have access to support from their case manager through a phone app or calls. This study has been approved by a local ethics committee to ensure the safety and well-being of all participants.

Gender

ALL

Eligibility criteria

• Inclusion Criteria:
• • Age ≥ 18 years.
• • Previous diagnosis of bronchial asthma according to GEMA 5.4 criteria.
• • • Follow-up for at least 6 months in an asthma unit and absence of relevant uncontrolled comorbidities.
• • Classified as moderate or severe asthma according to therapeutic step at the beginning of the study, as defined by GEMA 5.4.
• • Signed informed consent form.
• Exclusion Criteria:
• • Simultaneous presence of other diseases that may simulate asthma symptoms (COPD, left heart failure, functional dyspnea/hyperventilation syndrome, inducible laryngeal obstruction...).
• • Severe psychosocial problems or any other clinical situation that prevents the signature of the informed consent and/or the follow-up proposed in the study.
• • Lack of minimum technological knowledge for the use of monitoring tools.